Ryan Sullivan, MD
Internal Medicine · Cambridge, MANPI 1881696003
Payments from drug & device makers
Across 715 payments — averaging $11,858 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.8M
- Genentech, Inc.$1.7M
- Modernatx, Inc.$1.2M
- Novartis$915K
- Eli Lilly$602K
- Sanofi US Services Inc.$538K
- plus $1.7M from 16 others
Across 16 payments — averaging $2535.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$21K
- Pfizer$12K
- Novartis$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 35 | $1,790,295 |
| Genentech, Inc. | 127 | $1,707,110 |
| Modernatx, Inc. | 188 | $1,211,320 |
| Novartis | 27 | $914,720 |
| Eli Lilly | 17 | $602,037 |
| Sanofi US Services Inc. | 23 | $538,355 |
| Immunocore Limited | 52 | $480,907 |
| Alkermes, Inc. | 43 | $275,017 |
| Amgen | 1 | $259,623 |
| Otsuka Pharmaceutical Co., Ltd. | 32 | $227,176 |
| Array Biopharma Inc | 14 | $114,830 |
| Tesaro, Inc. | 10 | $89,653 |
| Springworks Therapeutics, Inc. | 64 | $83,636 |
| Pfizer | 32 | $82,851 |
| GSK | 30 | $78,547 |
| E.r. Squibb & Sons, L.L.C. | 6 | $10,922 |
| Taiho Oncology, Inc. | 3 | $8,425 |
| Eisai Inc. | 1 | $1,719 |
| Astrazeneca UK Limited | 1 | $1,000 |
| Biontech SE | 7 | $484 |
| Clinigen, Inc. | 1 | $145 |
| Genentech USA, Inc. | 1 | $4 |
How this compares
$8,478,776 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Cambridge
- William SellersCambridge$5M
- Alan GarberCambridge$4.9M
- Amy ColsonCambridge$604K
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.